Jiangsu Aoyang Health Industry Co.ltd. (SHE:002172)
China · Delayed Price · Currency is CNY 3.880
-0.150 (-3.72%)
Apr 3, 2026, 3:04 PM CST
SHE:002172 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,807 | 1,999 | 2,165 | 2,008 | 1,429 |
Other Revenue | - | 10.29 | 8.48 | 13.77 | - |
| 1,807 | 2,010 | 2,174 | 2,021 | 1,429 | |
Revenue Growth (YoY) | -10.10% | -7.54% | 7.54% | 41.41% | -24.18% |
Cost of Revenue | 1,559 | 1,745 | 1,885 | 1,741 | 989.31 |
Gross Profit | 247.39 | 264.64 | 289.06 | 280.15 | 440.06 |
Selling, General & Admin | 137.72 | 162.56 | 189.61 | 198.57 | 370.95 |
Other Operating Expenses | -4.54 | 11.07 | 11.01 | 11.52 | 30.59 |
Operating Expenses | 133.18 | 177.14 | 203.48 | 164.97 | 453.88 |
Operating Income | 114.22 | 87.49 | 85.58 | 115.17 | -13.82 |
Interest Expense | - | -39.38 | -43.19 | -62.56 | -137.76 |
Interest & Investment Income | 2.15 | 22.5 | 45.19 | 19.04 | 15.85 |
Currency Exchange Gain (Loss) | - | 0.01 | 0.02 | 0.07 | -0.03 |
Other Non Operating Income (Expenses) | -53.93 | -13.82 | -10.74 | -54.46 | -16.64 |
EBT Excluding Unusual Items | 62.44 | 56.81 | 76.87 | 17.26 | -152.4 |
Gain (Loss) on Sale of Investments | -0.3 | -1.31 | - | -15.89 | -3.98 |
Gain (Loss) on Sale of Assets | 0.01 | -0.06 | 0.03 | -0.01 | 8.8 |
Asset Writedown | -2.45 | -0.14 | -1 | -0.05 | -745.14 |
Legal Settlements | - | - | -17.46 | -20 | - |
Other Unusual Items | - | 9.88 | 11.51 | 17.72 | 53.24 |
Pretax Income | 59.7 | 65.18 | 69.94 | -0.96 | -839.48 |
Income Tax Expense | 17.81 | 23.94 | 19.68 | 14.76 | -11.43 |
Earnings From Continuing Operations | 41.88 | 41.24 | 50.26 | -15.72 | -828.05 |
Earnings From Discontinued Operations | - | - | - | - | -239.15 |
Net Income to Company | 41.88 | 41.24 | 50.26 | -15.72 | -1,067 |
Minority Interest in Earnings | -0.59 | -0.68 | -0.58 | 0.36 | 28.28 |
Net Income | 41.29 | 40.56 | 49.68 | -15.37 | -1,039 |
Net Income to Common | 41.29 | 40.56 | 49.68 | -15.37 | -1,039 |
Net Income Growth | 1.80% | -18.36% | - | - | - |
Shares Outstanding (Basic) | 826 | 811 | 828 | 768 | 775 |
Shares Outstanding (Diluted) | 826 | 811 | 828 | 768 | 775 |
Shares Change (YoY) | 1.80% | -2.03% | 7.78% | -0.91% | -0.34% |
EPS (Basic) | 0.05 | 0.05 | 0.06 | -0.02 | -1.34 |
EPS (Diluted) | 0.05 | 0.05 | 0.06 | -0.02 | -1.34 |
EPS Growth | - | -16.67% | - | - | - |
Free Cash Flow | -19.96 | -28.2 | -9.29 | -226.97 | -254.58 |
Free Cash Flow Per Share | -0.02 | -0.04 | -0.01 | -0.29 | -0.33 |
Gross Margin | 13.69% | 13.17% | 13.30% | 13.86% | 30.79% |
Operating Margin | 6.32% | 4.35% | 3.94% | 5.70% | -0.97% |
Profit Margin | 2.28% | 2.02% | 2.29% | -0.76% | -72.68% |
Free Cash Flow Margin | -1.10% | -1.40% | -0.43% | -11.23% | -17.81% |
EBITDA | 169.02 | 141.28 | 149.83 | 183.18 | 199.8 |
EBITDA Margin | 9.35% | 7.03% | 6.89% | 9.06% | 13.98% |
D&A For EBITDA | 54.8 | 53.79 | 64.25 | 68.01 | 213.63 |
EBIT | 114.22 | 87.49 | 85.58 | 115.17 | -13.82 |
EBIT Margin | 6.32% | 4.35% | 3.94% | 5.70% | -0.97% |
Effective Tax Rate | 29.84% | 36.72% | 28.14% | - | - |
Revenue as Reported | - | 2,010 | 2,174 | 2,021 | 3,029 |
Advertising Expenses | - | 2.46 | 1.91 | 2 | 3.27 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.